USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BioAMPS International LLC
Address:
12635 Montview Blvd. Suite 100
Aurora, CO 80045-
Phone:
(303) 921-5789
URL:
N/A
EIN:
262610248
DUNS:
18876967
Number of Employees:
1
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $69,960.00 1
STTR Phase II $493,619.00 1

Award List:

Rationally-designed, D-conformation Antimicrobial Peptides as Novel Antibacterial Drug Candidates for the Treatment of Multi-drug-resistant Bacterial

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$69,960.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Robert Hodges, Principal Investigator
Research Institution:
University of Colorado Denver
RI Contact:
Lora Milhelic
Abstract:
Antimicrobial resistance is among the most challenging problems in microbiology and clinical medicine, and the DOD has seen a dramatic increase of resistant strains of MRSA and multi-drug-resistant Acinetobacter baumanii (MDR-AB) emerging in combat- and non-combat-related healthcare settings. … More

Rationally-designed, D-conformation Antimicrobial Peptides as Novel Antibacterial Drug Candidates for the Treatment of Multi-drug-resistant Bacterial

Award Year / Program / Phase:
2011 / STTR / Phase II
Award Amount:
$493,619.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Robert Hodges, Principal Investigator – (303) 724-3253
Research Institution:
University of Colorado, Denver
RI Contact:
Robert Hodges
Abstract:
The goal of this Navy Phase II STTR project is to identify and develop a D-conformation antimicrobial peptide as a novel, effective, and safe antibacterial drug candidate capable of entering human clinical trials. From a set of 4 uniquely designed analogs that exhibit superior in vitro biologic… More